Reviva Pharmaceutcls Hldgs Inc Stock Price, News & Analysis

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced a registered direct offering of 3,359,684 shares at $2.53 per share, yielding gross proceeds of approximately $8.5 million. This offering involves a healthcare-focused institutional investor and Board member affiliates, including unregistered warrants with an exercise price of $2.40. The funds will support clinical development of brilaroxazine (RP5063) for schizophrenia and general corporate purposes. The closing is anticipated around September 8, 2022, pending customary conditions.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported financial results for Q2 2022, showing a net loss of approximately $5.3 million, or ($0.29) per share, compared to $1.6 million, or ($0.12) per share, in Q2 2021. Cash reserves were approximately $19.4 million as of June 30, 2022, down from $29.7 million at the end of 2021. The company is advancing its pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia, with over 20% of the planned 400 patients already enrolled. Topline data is expected in mid-2023, and expansion into additional indications is being explored.

Reviva Pharmaceuticals (RVPH) has announced progress in its Phase 3 clinical trial for brilaroxazine, targeting schizophrenia, with over 20% of the 400 patients already enrolled across 15 U.S. sites. Enrollment is set to expand to Europe and India in Q3 2022. Positive results from the prior Phase 2 trial support brilaroxazine’s efficacy, including a 20-point reduction in the PANSS score. Reviva plans to initiate Phase 2a trials for ADHD and Pulmonary Arterial Hypertension in Q4 2022, highlighting a robust pipeline aimed at addressing unmet medical needs.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced participation in the 2022 BIO International Convention from June 13-16 in San Diego, CA. Laxminarayan Bhat, Ph.D., Founder and CEO, is set to present on June 14 at 12:15 p.m. PT. The company focuses on developing therapies for unmet medical needs in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's pipeline includes RP5063 (brilaroxazine) and RP1208, both with granted patents in key markets.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announces that CEO Laxminarayan Bhat will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation is scheduled for May 25 at 3:00 p.m. ET, available both in-person in Miami and through virtual one-on-one meetings. Reviva focuses on addressing unmet medical needs in CNS, cardiovascular, metabolic, and inflammatory diseases, with candidates RP5063 and RP1208 in their pipeline. For further details and registration, visit the conference's official website.

Reviva Pharmaceuticals (RVPH) reported a net loss of approximately $7.4 million or $0.40 per share for Q1 2022, an increase from $0.9 million or $0.10 per share in Q1 2021. As of March 31, 2022, cash reserves totaled $23.4 million, down from $29.7 million at year-end 2021, but projected to fund operations until at least March 2023. The company has initiated a pivotal Phase 3 trial for its lead asset, brilaroxazine, targeting schizophrenia. Topline data is expected in mid-2023.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced positive progress in its Phase 3 RECOVER study for brilaroxazine, a treatment for acute schizophrenia. All U.S. clinical sites are active, with global sites in Europe and India to initiate mid-2022. The study involves approximately 400 patients, assessing safety and efficacy with no serious treatment-related adverse events reported to date. Results are expected in mid-2023, which could significantly impact Reviva’s market position and future growth.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) will host a key opinion leader (KOL) webinar on brilaroxazine (RP5063) for schizophrenia and neuropsychiatric disorders on May 3, 2022 at 10:00 AM ET. The event will cover unmet medical needs in these areas and feature experts Leslie Citrome, MD, and Larry Ereshefsky, PharmD. Reviva’s CEO, Dr. Laxminarayan Bhat, will present clinical data supporting the Phase 3 evaluation of brilaroxazine, a potential treatment targeting serotonin and dopamine receptors implicated in schizophrenia.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced an upcoming interview with CEO Dr. Laxminarayan Bhat on The RedChip Money Report®, airing on Bloomberg TV at 7 p.m. ET on March 26, 2022. The segment, aimed at investors, covers small-cap market insights and features executive interviews. Reviva focuses on developing therapies for unmet medical needs in central nervous system, respiratory, and metabolic diseases, with two proprietary drug candidates, RP5063 and RP1208, both secured with composition of matter patents in multiple markets.